Pfizer's Vyndaqel and Vyndamax (tafamidis) treatments for TTR amyloidosis
0 Views
administrator
07/08/23
Dr. Adam Castano, Sr. Medical Director for ATTR Cardiac Amyloidosis at Pfizer, presents an update on Vyndaqel/Vyndamax (tafamidis), Pfizer's TTR stabilizer treatment, at ASG's 12/05/2020 ATTR webinar.
-
Category
Show more
Facebook Comments
No comments found